Standard BioTools Inc. Accounts Payable
Standard BioTools Inc. (LAB) had Accounts Payable of $9.55 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-05
- 2026-06-30: Accounts Payable, Current $9.55M.
- 2026-03-31: Accounts Payable, Current $8.01M.
- 2025-12-31: Accounts Payable, Current $5.41M.
- 2025-09-30: Accounts Payable, Current $6.62M.
| Period end | Accounts Payable, Current | Accounts Payable, Current as first filed |
|---|---|---|
| 2026-06-30 | $9.55M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $8.01M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $5.41M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $6.62M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $7.33M 10-Q · filed 2025-08-15 | |
| 2025-03-31 | $11.78M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $5.05M 10-K · filed 2026-03-16 | $12.28M 10-K · filed 2025-03-11 |
| 2024-09-30 | $10.93M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $12.57M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $13.14M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $9.24M 10-K · filed 2025-03-11 | |
| 2023-09-30 | $7.33M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $6.09M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $6.11M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $7.91M 10-K · filed 2024-03-01 | |
| 2022-09-30 | $9.30M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $9.02M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $12.52M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $10.60M 10-K · filed 2023-03-14 | |
| 2021-09-30 | $10.79M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $11.22M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $12.55M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $9.22M 10-K · filed 2022-03-08 | |
| 2020-09-30 | $10.97M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $9.38M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $9.44M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $5.15M 10-K · filed 2021-02-25 | $6.51M 10-K · filed 2020-02-27 |
| 2019-09-30 | $5.34M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $8.07M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $6.94M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $4.03M 10-K · filed 2020-02-27 | |
| 2018-09-30 | $6.25M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $6.64M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $5.21M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $4.21M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $4.72M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $3.86M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $3.73M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $3.97M 10-K · filed 2018-03-08 | |
| 2016-09-30 | $4.87M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $5.83M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $4.44M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $6.09M 10-K · filed 2017-03-03 | |
| 2015-09-30 | $6.30M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $5.96M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $5.50M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $5.92M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $7.28M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $7.64M 10-Q · filed 2014-08-04 | |
| 2014-03-31 | $8.00M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $4.35M 10-K · filed 2015-02-26 | |
| 2013-09-30 | $3.41M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $2.00M 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $3.21M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $2.56M 10-K · filed 2014-03-12 | |
| 2012-09-30 | $3.35M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $3.29M 10-Q · filed 2012-08-14 | |
| 2012-03-31 | $4.10M 10-Q · filed 2012-05-15 | |
| 2011-12-31 | $4.01M 10-K · filed 2013-03-12 | |
| 2011-09-30 | $4.68M 10-Q · filed 2011-11-14 | |
| 2011-06-30 | $2.98M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $3.15M 10-K · filed 2012-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |